Treatment of Tardive Dyskinesia With Galantamine

Completed · Phase 4

Conditions studied: Tardive Dyskinesia

In brief

Tardive dyskinesia (TD), a form of movement disorder, remains a problem for some patients who received antipsychotic medications. Increasing evidence suggests that TD may result from antipsychotic-induced dysfunction in striatal cholinergic neurons. To test whether cholinesterase inhibitors compensate for diminished cholinergic activity underlying TD, we conducted a 30-week randomized, double-blind, placebo-controlled crossover study of galantamine in 36 patients with TD.

Key facts

Study ID

NCT00164242

Run by

Caroff, Stanley N., M.D.

People needed

36

Starts

2002-01-01

Expected to finish

2004-10-01

Last updated by the study team

2005-09-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of tardive dyskinesia lasting at least 3 months
• Treatment with antipsychotic drugs at least for 3 months
• 18 years old or older

You may not qualify if…

• Significant active medical illness
• Allergy to galantamine
• Pregnancy
• Drug or alcohol dependence
• Necessary use of anticholinergics or vitamin E

Where it is running

• Philadelphia VA Medical Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.